Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity?

Löfvendahl, Sofia; Petersson, Ingemar F; Theander, Elke; Svensson, Åke; Zhou, Caddie; Carlsson, Katarina Steen

doi:10.3899/jrheum.150406

Cited by 11 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Psoriasis is a chronic disease requiring effective long-term treatment to manage the debilitating consequences, and societal and economic burden of disease (23,24). However, drug survival data from the DERMBIO registry, which contains data on all Danish patients with moderate-to-severe psoriasis treated with biologics, indicate that the investigated biologic drugs (adalimumab, etanercept, infliximab, secukinumab, and ustekinumab) may eventually all lose efficacy ( Figure 1) (2).…”

Section: Drug Survivalmentioning

confidence: 99%

Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

Barker

Girolomoni

Egeberg

et al. 2019

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Tumor necrosis factor (TNF) inhibitors account for a large proportion of drugs used to treat psoriasis and are indicated first-line options in certain settings. Several biosimilar drugs based on the anti-TNF agents adalimumab, infliximab, and etanercept are now available for use in patients with psoriasis. The favorable cost differential of biosimilars is expected to improve access to biologic therapy for biologic-naive psoriasis patients, who are often undertreated. Also, substantial cost savings can be made if patients are switched to biosimilars. To date, most clinical testing of anti-TNF biosimilars approved for use in psoriasis has been performed in patients with rheumatoid arthritis, and the results extrapolated to psoriasis. Although this may initially raise concerns for clinicians looking to start their psoriasis patients on biologic treatment with a biosimilar or switch from an original biologic to a biosimilar, the process of extrapolation is tightly regulated and scientifically justified. Furthermore, available real-world evidence of the safety and efficacy of anti-TNF agents in patients with psoriasis complements clinical trial data in patients with rheumatoid arthritis. When equipped with the appropriate knowledge, clinicians should have confidence to use biosimilars for the treatment of psoriasis.

show abstract

Section: Drug Survivalmentioning

confidence: 99%

Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

Barker

Girolomoni

Egeberg

et al. 2019

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…According to a study by the National Psoriasis Foundation (NPF), 49% of people with psoriasis and/or PsA miss work regularly due to illness [7]. Generally, it is estimated that around 20-40% of the total costs of psoriasis are attributable to productivity and work loss [17][18][19][20][21][22]. Among patients with PsA, it has been found that work disability rates range from 23 to 39% [23,24].…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, a study that used an employment disadvantages questionnaire to compare patients with psoriasis and PsA found an increased rate of work problems caused by PsA (32% versus 11% for psoriasis; p < 0.0005) [ 25 ]. Similarly, productivity loss has been shown to be greater among patients with PsA compared with those with other inflammatory diseases such as psoriasis, ankylosing spondylitis, rheumatoid arthritis [ 22 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA—a retrospective study of claims data from 2009 TO 2020

Orbai

Reddy

Dennis³

et al. 2021

Clin Rheumatol

View full text Add to dashboard Cite

Objectives To compare work absenteeism and short-term disability among adults with psoriasis or psoriatic arthritis (PsA), versus controls in the USA. Methods Adults eligible for work absenteeism and/or short-term disability benefits between 1/1/2009 and 4/30/2020 were screened in the IBM® MarketScan® Commercial and Health and Productivity Management Databases. The following groups were defined: (1) psoriasis: ≥ 2 psoriasis diagnoses ≥ 30 days apart and no PsA diagnoses; (2) PsA: ≥ 2 PsA diagnoses ≥ 30 days apart; (3) control: absence of psoriasis and PsA diagnoses. Controls were matched to psoriasis and PsA patients based on age, gender, index year, and comorbidities. Non-recreational work absences and sick leaves were evaluated in absentee-eligible patients, and short-term disability was evaluated in short-term disability-eligible patients. Costs (in 2019 USD) associated with each type of work absence were evaluated. Results 4261 psoriasis and 616 PsA absentee-eligible and 25,213 psoriasis and 3480 PsA short-term disability-eligible patients were matched to controls. Average non-recreational work absence costs were $1681, $1657, and $1217 for the PsA, psoriasis, and control group, respectively. Compared with psoriasis patients and controls, more PsA patients had sick leaves after 1 year (56.2% versus 55.6% and 41.5%, p < 0.0001). Similarly, short-term disability was more frequent in PsA patients than psoriasis patients and controls at year one (8.8% versus 5.6% and 4.7%, p < 0.0001) and corresponding costs were higher ($605, $406, and $335 on average, p < 0.0001). Conclusion Annual work absenteeism and short-term disability were consistently greater among patients with PsA and psoriasis than controls, highlighting the substantial economic burden of psoriatic disease. Key points• Patients with PsA had greater short-term disability compared with patients with psoriasis and patients with neither psoriasis nor PsA.• Patients with PsA and patients with psoriasis incurred greater non-recreational work absences and sick leaves than patients with neither psoriasis nor PsA.

show abstract

“…Psoriasis leads to cumulative life course impairment . In comparison with a referent cohort and a matched control group including a random mix of other diseases, psoriasis is known to produce higher costs . The economic burden for the patient and for society has been shown by several authors .…”

Section: Introductionmentioning

confidence: 99%

Cost‐of‐illness of psoriasis – results of a German cross‐sectional study

Jungen

Augustin

Langenbruch

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity?

Cited by 11 publications

References 39 publications

Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA—a retrospective study of claims data from 2009 TO 2020

Cost‐of‐illness of psoriasis – results of a German cross‐sectional study

Contact Info

Product

Resources

About